SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$174M
Q4 2020
Positions
48
Filings on Record
39
2019–present window
Filed
Feb 9, 2021
original filing

Summary

Birchview Capital, LP reported $174M in U.S.-listed holdings across 48 positions for Q4 2020.

The portfolio is heavily concentrated: BMY alone accounts for 28.4% of reported value.

Compared with Q3 2020, the fund opened 3 new positions and exited 5.

Portfolio Metrics

Turnover
+12.1%
vs prior filed quarter
Top-10 Concentration
+75.0%
share of reported value
Largest Position
+28.4%
Bristol Myers Squibb
New / Exited
3 / 5
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 66.8%Other: 32.7%Right: 0.4%
  • Common Stock · 66.8% · $116M
  • Other · 32.7% · $57M
  • Right · 0.4% · $763,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BIODESIX INCNEW+1.11M1.11M+$22M$22M
FHTXFOGHORN THERAPEUTICS INCNEW+314.1K314.1K+$6M$6M
PROGENITY INCNEW+250.0K250.0K+$1M$1M
MYOKEURMYOKARDIA INCSOLD OUT−10.0K0−$1M$0
EPZMEUREPIZYME INCSOLD OUT−70.0K0−$835,000$0
ICPTUSDINTERCEPT PHARMACEUTICALS INCSOLD OUT−8.3K0−$344,000$0
VYGRVOYAGER THERAPEUTICS INCSOLD OUT−30.0K0−$320,000$0
WKHSEURWORKHORSE GROUP INCSOLD OUT−8.0K0−$202,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

48 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM28.39%$49M794.4K
2BIODESIX INCCOM12.83%$22M1.11M
3ACCELERATE DIAGNOSTICS INCCOM9.58%$17M2.19M
4QDEL*QUIDEL CORPhistory →COM6.07%$11M58.6K
5NBIXNEUROCRINE BIOSCIENCES INChistory →COM4.43%$8M80.2K
6FHTXFOGHORN THERAPEUTICS INChistory →COM3.67%$6M314.1K
7ASPIRA WOMENS HEALTH INCCOM3.24%$6M840.1K
8ACADACADIA PHARMACEUTICALS INChistory →COM3.14%$5M102.0K
9BDQMALBIREO PHARMA INChistory →COM1.99%$3M92.0K
10OXFORD IMMUNOTEC GLOBAL PLCCOM1.71%$3M170.3K
11BIIBBIOGEN INChistory →COM1.71%$3M12.1K
12KPTIEURKARYOPHARM THERAPEUTICS INChistory →COM1.68%$3M188.0K
13UTHUNITED THERAPEUTICS CORPhistory →COM1.57%$3M18.0K
14BLUEBIRD BIO INCCOM1.55%$3M62.0K
15XLRNACCELERON PHARMA INChistory →COM1.38%$2M18.7K
16MASI*MASIMO CORPhistory →COM1.24%$2M8.0K
17CCXIEURCHEMOCENTRYX INChistory →COM1.07%$2M30.0K
18ARNAEURARENA PHARMACEUTICALS INCCOM0.97%$2M22.0K
19SOLENO THERAPEUTICS INCCOM0.92%$2M826.9K
20AMARIN CORP PLCSPONS ADR NEW0.85%$1M300.0K
21PROGENITY INCCOM0.77%$1M250.0K
22HTDCORCEPT THERAPEUTICS INCCOM0.75%$1M50.0K
23ARVNARVINAS INCCOM0.73%$1M15.0K
24STOKSTOKE THERAPEUTICS INCCOM0.71%$1M20.0K
25HROWHARROW HEALTH INCCOM0.71%$1M180.0K
26IMGNEURIMMUNOGEN INCCOM0.71%$1M190.0K
27ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.62%$1M133.1K
28VNDAVANDA PHARMACEUTICALS INCCOM0.61%$1M80.0K
29CFRXEURCONTRAFECT CORPCOM0.58%$1M200.0K
30AM6AMICUS THERAPEUTICS INCCOM0.51%$877,00038.0K
31BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.49%$857,00010.0K
32TGTXTG THERAPEUTICS INCCOM0.45%$780,00015.0K
33BMY-RBMY CVR RTS 03/31/21RIGHT0.44%$763,0001.11M
34GTHXEURG1 THERAPEUTICS INCCOM0.41%$720,00040.0K
35PGNYPROGYNY INCCOM0.37%$636,00015.0K
36CLRUSDCONTINENTAL RESOURCES INCCOM0.36%$629,00038.6K
37INARI MEDICAL INCCOM0.35%$611,0007.0K
384XC1KALVISTA PHARMACEUTICALS INCCOM0.33%$570,00030.0K
39TRANSLATE BIO INCCOM0.32%$553,00030.0K
40XNCRXENCOR INCCOM0.31%$537,00012.3K
41OVVOVINTIV INCCOM0.28%$493,00034.4K
42APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.26%$458,0008.0K
43PXDEURPIONEER NATURAL RESOURCES COCOM0.25%$433,0003.8K
44ODONATE THERAPEUTICS INCCOM0.22%$384,00020.0K
45INFLARX NVCOM0.20%$352,00070.0K
46DRNAUSDDICERNA PHARMACEUTICALS INCCOM0.13%$220,00010.0K
47BCRXBIOCRYST PHARMACEUTICALS INCCOM0.09%$149,00020.0K
48YIELD10 BIOSCIENCE INCCOM0.06%$110,00019.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.